Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018220546) CRYSTALLINE FORMS OF 5-BROMO-2,6-DI(1 H-PYRAZOL-1-YL)PYRIMIDIN-4-AMINE AND NEW SALTS
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/220546 International Application No.: PCT/IB2018/053839
Publication Date: 06.12.2018 International Filing Date: 30.05.2018
IPC:
C07D 403/14 (2006.01) ,A61P 35/00 (2006.01) ,A61K 31/506 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
403
Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/167
14
containing three or more hetero rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
506
not condensed and containing further heterocyclic rings
Applicants:
NOVARTIS AG [CH/CH]; Lichtstrasse 35 4056 Basel, CH
Inventors:
CUI, Kai; CN
KONG, Weiyong; CN
CASTRO-PALOMINO LARIA, Julio Cesar; ES
Priority Data:
PCT/CN2017/08662431.05.2017CN
Title (EN) CRYSTALLINE FORMS OF 5-BROMO-2,6-DI(1 H-PYRAZOL-1-YL)PYRIMIDIN-4-AMINE AND NEW SALTS
(FR) FORMES CRISTALLINES DE 5-BROMO-2,6-DI(1 H-PYRAZOL-1-YL)PYRIMIDIN-4-AMINE ET NOUVEAUX SELS
Abstract:
(EN) This application relates to various crystalline forms of 5-bromo-2,6-di(1H-pyrazol-1- yl)pyrimidin-4-amine and salt thereof, as well as compositions and methods of using the same. In some embodiments the crystalline forms also contain water ("hydrates"). These materials are useful in the treatment of various diseases, including carcinomas, specifically lung cancer and more specifically non-small cell lung cancer.
(FR) La présente invention concerne diverses formes cristallines de 5-bromo-2,6-di(1H-pyrazol-1- yl)pyrimidin-4-amine et un sel de celles-ci, ainsi que des compositions et des procédés d'utilisation de celles-ci. Dans certains modes de réalisation, les formes cristallines contiennent également de l'eau ("hydrates"). Les matériaux de l'invention sont utiles dans le traitement de diverses maladies, y compris des carcinomes, en particulier le cancer du poumon et plus particulièrement le cancer du poumon non à petites cellules.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)